Novo Nordisk and Eli Lilly are reporting Q2 earnings this week, as Novo's Wegovy pill outsells Lilly's Foundayo and a dealmaking divide develops between the obesity rivals.
For years, Novo Nordisk and Eli Lilly have dominated the conversation surrounding obesity medicines as the duopoly competes to lead the largest pharmaceutical category in …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Lilly climbs, Novo falls as obesity drug battle intensifies
GLP-1 battle heats up again as Novo claws its way back into race with Lilly
Novo Dives On A Key Miss As Its Battle With Lilly Heats Up
Lilly’s obesity pill Foundayo ‘disappointed’ in Q2, as injectables continue to boom
A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed…
Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare.
The market leader in obesity shots, Lilly hasn’t made a major dent in the pill market yet.
The two pharmaceutical giants are locked in a fierce battle for dominance in the burgeoning obesity drug market
Eli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medication: pills.
In Novo Nordisk and Eli Lilly’s competition to launch their respective GLP-1 obesity pills in the United States, the Danish…
